Clinical Trial Update: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating vandetanib (ZD6474) plus bortezomib in adults with medullary thyroid carcinoma; study status TERMINATED with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Bortezomib (bortezomib)
• Vandetanib (vandetanib)
• Velcade (bortezomib)
• Zactima (vandetanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Medullary Thyroid Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-05-17